Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
The company is the leading maker of cystic fibrosis (CF) treatments, with its products generating more than $9.8 billion in revenue last year. Vertex also recently submitted its latest CF candidate to regulators for consideration -- and an approval could truly cement its long-term dominance. On top of this, late last year Vertex won approval -- along with partner CRISPR Therapeutics (NASDAQ: CRSP) -- for Casgevy, a gene-editing therapy for blood disorders. It showed that the big biotech can indeed expand beyond its CF specialty. And Vertex is continuing this with its recent rolling regulatory submission of its candidate for pain. So, over time, Vertex has become a company with multiple products and multiple treatment areas, helping it to generate billions of dollars in earnings. The stock price followed, climbing more than 145% over the past three years. Vertex remains an excellent investment, but investors also may want to try to get in on the next Vertex while the player is in
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- This Healthcare Growth Stock Could Be a Steal of a Deal Right Now [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Royal Bank of Canada from $60.00 to $53.00. They now have a "sector perform" rating on the stock.MarketBeat
CRSP
Earnings
- 8/5/24 - Miss
CRSP
Sec Filings
- 10/15/24 - Form 4
- 10/15/24 - Form 4
- 8/12/24 - Form 4
- CRSP's page on the SEC website